Notably, the development of glycoconjugates as potent entry inhibitors to block virus binding and infecting host cells can be advantageous over other anti-viral strategies because this can effectively prevent virus mutation and develop resistance. This can be particularly beneficial for controlling infections induced by unstable RNA viruses, including SARS-CoV-2, where rapid mutations and variations can lead to effective evasion of host antibody responses induced by past infections and/or vaccines.